PMC:7755033 / 93070-95635
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"1806","span":{"begin":63,"end":65},"obj":"Species"},{"id":"1807","span":{"begin":130,"end":138},"obj":"Chemical"},{"id":"1808","span":{"begin":140,"end":152},"obj":"Chemical"},{"id":"1809","span":{"begin":154,"end":164},"obj":"Chemical"},{"id":"1810","span":{"begin":166,"end":173},"obj":"Chemical"},{"id":"1811","span":{"begin":175,"end":193},"obj":"Chemical"},{"id":"1812","span":{"begin":195,"end":205},"obj":"Chemical"},{"id":"1813","span":{"begin":207,"end":217},"obj":"Chemical"},{"id":"1817","span":{"begin":1644,"end":1647},"obj":"Gene"},{"id":"1818","span":{"begin":1494,"end":1497},"obj":"Gene"},{"id":"1819","span":{"begin":1353,"end":1356},"obj":"Gene"}],"attributes":[{"id":"A1806","pred":"tao:has_database_id","subj":"1806","obj":"Tax:126910"},{"id":"A1808","pred":"tao:has_database_id","subj":"1808","obj":"MESH:D011342"},{"id":"A1809","pred":"tao:has_database_id","subj":"1809","obj":"MESH:D000069449"},{"id":"A1810","pred":"tao:has_database_id","subj":"1810","obj":"MESH:C086979"},{"id":"A1811","pred":"tao:has_database_id","subj":"1811","obj":"MESH:D006886"},{"id":"A1813","pred":"tao:has_database_id","subj":"1813","obj":"MESH:C557213"},{"id":"A1817","pred":"tao:has_database_id","subj":"1817","obj":"Gene:3853"},{"id":"A1818","pred":"tao:has_database_id","subj":"1818","obj":"Gene:3854"},{"id":"A1819","pred":"tao:has_database_id","subj":"1819","obj":"Gene:7163"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 16. Bravais–Pearson (linear correlation) coefficient of WS phytoconstituents versus FDA-approved standard reference drugs (Losartan, Procainamide, Cinacalcet, Arbidol, Hydroxychloroquine, Oberadilol, Poziotinib) for physicochemical properties.\nProperties 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16\n% AB 1 –0.719 –0.867 0.387 –0.807 0.0443 –1 0.274 0.99 –0.0259 0.037 –0.0781 0.0966 –0.0537 0.0186 5.38E–05\n(NOHNH) 2 –0.719 0.582 –0.357 0.399 0.243 0.719 –0.466 –0.779 0.214 0.45 –0.346 0.156 0.032 –0.0146 –1.39E–08\n(NON) 3 –0.867 0.582 0.0762 0.938 –0.0124 0.867 0.11 –0.893 –0.397 –0.147 –0.119 –0.00919 –0.0307 0.0873 2.76E–09\nLV 4 0.387 –0.357 0.0762 0.0607 0.182 –0.387 0.76 0.35 –0.822 –0.0907 –0.427 –0.103 –0.00279 –0.0306 1.09E–08\nMW 5 –0.807 0.399 0.938 0.0607 0.012 0.807 0.278 –0.821 –0.491 –0.203 0.157 0.0848 –0.0985 –0.0469 5.89E–10\nRB 6 0.0443 0.243 –0.0124 0.182 0.012 –0.0443 0.363 0.0185 –0.386 0.905 0.157 –0.0754 –0.0364 0.00653 4.45E–09\nTPSA 7 –1 0.719 0.867 –0.387 0.807 –0.0443 –0.274 –0.99 0.0259 –0.0371 0.0782 –0.0964 0.0537 –0.0186 5.38E–05\nclog Pc 8 0.274 –0.466 0.11 0.76 0.278 0.363 –0.274 0.264 –0.931 –0.0242 0.205 0.112 0.0929 0.00734 –1.71E–08\npc1 9 0.99 –0.779 –0.893 0.35 –0.821 0.0185 –0.99 0.264 9.62E–09 –8.89E–09 5.33E–09 –1.73E–08 6.60E–09 –5.23E–09 1.16E–08\npc2 10 –0.0259 0.214 –0.397 –0.822 –0.491 –0.386 0.0259 –0.931 9.62E–09 –5.16E–09 –9.75E–09 –1.46E–08 –1.70E–09 3.02E–10 –8.98E–10\npc3 11 0.037 0.45 –0.147 –0.0907 –0.203 0.905 –0.0371 –0.0242 –8.89E–09 –5.16E–09 1.02E–08 –8.09E–09 –2.00E–09 –2.34E–08 –1.94E–08\npc4 12 –0.0781 –0.346 –0.119 –0.427 0.157 0.157 0.0782 0.205 5.33E–09 –9.75E–09 1.02E–08 –7.30E–09 9.18E–09 –6.69E–09 5.02E–09\npc5 13 0.0966 0.156 –0.00919 –0.103 0.0848 –0.0754 –0.0964 0.112 –1.73E–08 –1.46E–08 –8.09E–09 –7.30E–09 4.55E–09 9.35E–09 2.03E–09\npc6 14 –0.0537 0.032 –0.0307 –0.00279 –0.0985 –0.0364 0.0537 0.0929 6.60E–09 –1.70E–09 –2.00E–09 9.18E–09 4.55E–09 6.33E–09 –1.14E–08\npc7 15 0.0186 –0.0146 0.0873 –0.0306 –0.0469 0.00653 –0.0186 0.00734 –5.23E–09 3.02E–10 –2.34E–08 –6.69E–09 9.35E–09 6.33E–09 –1.39E–08\npc8 16 5.38E–05 –1.39E–08 2.76E–09 1.09E–08 5.89E–10 4.45E–09 5.38E–05 –1.71E–08 1.16E–08 –8.98E–10 –1.94E–08 5.02E–09 2.03E–09 –1.14E–08 –1.39E–08 "}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T975","span":{"begin":0,"end":9},"obj":"Sentence"},{"id":"T976","span":{"begin":11,"end":250},"obj":"Sentence"},{"id":"T977","span":{"begin":251,"end":319},"obj":"Sentence"},{"id":"T978","span":{"begin":320,"end":446},"obj":"Sentence"},{"id":"T979","span":{"begin":447,"end":575},"obj":"Sentence"},{"id":"T980","span":{"begin":576,"end":708},"obj":"Sentence"},{"id":"T981","span":{"begin":709,"end":837},"obj":"Sentence"},{"id":"T982","span":{"begin":838,"end":964},"obj":"Sentence"},{"id":"T983","span":{"begin":965,"end":1094},"obj":"Sentence"},{"id":"T984","span":{"begin":1095,"end":1223},"obj":"Sentence"},{"id":"T985","span":{"begin":1224,"end":1352},"obj":"Sentence"},{"id":"T986","span":{"begin":1353,"end":1493},"obj":"Sentence"},{"id":"T987","span":{"begin":1494,"end":1643},"obj":"Sentence"},{"id":"T988","span":{"begin":1644,"end":1793},"obj":"Sentence"},{"id":"T989","span":{"begin":1794,"end":1939},"obj":"Sentence"},{"id":"T990","span":{"begin":1940,"end":2090},"obj":"Sentence"},{"id":"T991","span":{"begin":2091,"end":2243},"obj":"Sentence"},{"id":"T992","span":{"begin":2244,"end":2398},"obj":"Sentence"},{"id":"T993","span":{"begin":2399,"end":2565},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 16. Bravais–Pearson (linear correlation) coefficient of WS phytoconstituents versus FDA-approved standard reference drugs (Losartan, Procainamide, Cinacalcet, Arbidol, Hydroxychloroquine, Oberadilol, Poziotinib) for physicochemical properties.\nProperties 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16\n% AB 1 –0.719 –0.867 0.387 –0.807 0.0443 –1 0.274 0.99 –0.0259 0.037 –0.0781 0.0966 –0.0537 0.0186 5.38E–05\n(NOHNH) 2 –0.719 0.582 –0.357 0.399 0.243 0.719 –0.466 –0.779 0.214 0.45 –0.346 0.156 0.032 –0.0146 –1.39E–08\n(NON) 3 –0.867 0.582 0.0762 0.938 –0.0124 0.867 0.11 –0.893 –0.397 –0.147 –0.119 –0.00919 –0.0307 0.0873 2.76E–09\nLV 4 0.387 –0.357 0.0762 0.0607 0.182 –0.387 0.76 0.35 –0.822 –0.0907 –0.427 –0.103 –0.00279 –0.0306 1.09E–08\nMW 5 –0.807 0.399 0.938 0.0607 0.012 0.807 0.278 –0.821 –0.491 –0.203 0.157 0.0848 –0.0985 –0.0469 5.89E–10\nRB 6 0.0443 0.243 –0.0124 0.182 0.012 –0.0443 0.363 0.0185 –0.386 0.905 0.157 –0.0754 –0.0364 0.00653 4.45E–09\nTPSA 7 –1 0.719 0.867 –0.387 0.807 –0.0443 –0.274 –0.99 0.0259 –0.0371 0.0782 –0.0964 0.0537 –0.0186 5.38E–05\nclog Pc 8 0.274 –0.466 0.11 0.76 0.278 0.363 –0.274 0.264 –0.931 –0.0242 0.205 0.112 0.0929 0.00734 –1.71E–08\npc1 9 0.99 –0.779 –0.893 0.35 –0.821 0.0185 –0.99 0.264 9.62E–09 –8.89E–09 5.33E–09 –1.73E–08 6.60E–09 –5.23E–09 1.16E–08\npc2 10 –0.0259 0.214 –0.397 –0.822 –0.491 –0.386 0.0259 –0.931 9.62E–09 –5.16E–09 –9.75E–09 –1.46E–08 –1.70E–09 3.02E–10 –8.98E–10\npc3 11 0.037 0.45 –0.147 –0.0907 –0.203 0.905 –0.0371 –0.0242 –8.89E–09 –5.16E–09 1.02E–08 –8.09E–09 –2.00E–09 –2.34E–08 –1.94E–08\npc4 12 –0.0781 –0.346 –0.119 –0.427 0.157 0.157 0.0782 0.205 5.33E–09 –9.75E–09 1.02E–08 –7.30E–09 9.18E–09 –6.69E–09 5.02E–09\npc5 13 0.0966 0.156 –0.00919 –0.103 0.0848 –0.0754 –0.0964 0.112 –1.73E–08 –1.46E–08 –8.09E–09 –7.30E–09 4.55E–09 9.35E–09 2.03E–09\npc6 14 –0.0537 0.032 –0.0307 –0.00279 –0.0985 –0.0364 0.0537 0.0929 6.60E–09 –1.70E–09 –2.00E–09 9.18E–09 4.55E–09 6.33E–09 –1.14E–08\npc7 15 0.0186 –0.0146 0.0873 –0.0306 –0.0469 0.00653 –0.0186 0.00734 –5.23E–09 3.02E–10 –2.34E–08 –6.69E–09 9.35E–09 6.33E–09 –1.39E–08\npc8 16 5.38E–05 –1.39E–08 2.76E–09 1.09E–08 5.89E–10 4.45E–09 5.38E–05 –1.71E–08 1.16E–08 –8.98E–10 –1.94E–08 5.02E–09 2.03E–09 –1.14E–08 –1.39E–08 "}